Thomas Shrader
Stock Analyst at BTIG
(1.43)
# 3,155
Out of 4,784 analysts
46
Total ratings
32.5%
Success rate
-8.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $0.35 | +1,042.86% | 3 | Mar 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $11.58 | +254.06% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.29 | +287.60% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.31 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $69.46 | +130.35% | 4 | Sep 3, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $1.98 | +304.04% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.70 | +1,042.86% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $4.70 | +1,176.60% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $27.65 | -13.20% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $2.25 | +211.11% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.56 | +128.66% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.37 | +3,382.45% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $62.70 | -50.56% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.89 | +429.10% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.19 | +1,748.74% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $7.52 | +86.17% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.47 | +3,369.39% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.82 | +779.12% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.78 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $8.08 | +617.82% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.65 | +81.82% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $138.37 | +150.05% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.56 | - | 1 | Jun 30, 2017 |
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.35
Upside: +1,042.86%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $11.58
Upside: +254.06%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.29
Upside: +287.60%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $69.46
Upside: +130.35%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $1.98
Upside: +304.04%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.70
Upside: +1,042.86%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.70
Upside: +1,176.60%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $27.65
Upside: -13.20%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.25
Upside: +211.11%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.56
Upside: +128.66%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.37
Upside: +3,382.45%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $62.70
Upside: -50.56%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.89
Upside: +429.10%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.19
Upside: +1,748.74%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $7.52
Upside: +86.17%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.47
Upside: +3,369.39%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $1.82
Upside: +779.12%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.78
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $8.08
Upside: +617.82%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.65
Upside: +81.82%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $138.37
Upside: +150.05%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $1.56
Upside: -